[{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"JSKN003","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN026","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Jiangsu Alphamab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Jiangsu Alphamab","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Jiangsu Alphamab"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JSKN016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2023","type":"Inapplicable","leadProduct":"JSKN003","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JSKN016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"KN052","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JSKN016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Jiangsu Alphamab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Donafenib Tosilate","moa":"CRAF\/PDGFRs\/VEGFR","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Alphamab \/ Jiangsu Alphamab","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Jiangsu Alphamab"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2024","type":"Licensing Agreement","leadProduct":"Envafolimab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Glenmark Pharmaceuticals"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"JSKN033","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"JSKN033","moa":"HER2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"JSKN003","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Peking University","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN026","moa":"Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Peking University","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Peking University"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Jiangsu Alphamab","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Jiangsu Alphamab","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Alphamab \/ Jiangsu Alphamab"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Sunshine Lake Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"KN046","moa":"Cytotoxic T-lymphocyte protein 4 | Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Sunshine Lake Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Sunshine Lake Pharma"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Kintor Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GT90001","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Alphamab \/ Jiangsu Alphamab","highestDevelopmentStatusID":"7","companyTruncated":"Jiangsu Alphamab \/ Jiangsu Alphamab"},{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JSKN016","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Jiangsu Alphamab","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Alphamab \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Alphamab \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Jiangsu Alphamab
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
